Clinical Trial Update: Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM) [Phase 2]

View source ↗

Summary

Open-label extension study terminated; aims to characterize long-term safety and tolerability of elamipretide in genetically confirmed primary mitochondrial dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Disease

Drugs mentioned

• Elamipretide (elamipretide)

Snippet

Sponsor: Stealth BioTherapeutics Inc. | Conditions: Primary Mitochondrial Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-12-17